Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q3 FY25 results · Oct–Dec 2024
Aarti Pharmalabs reported revenue from operations of ₹537.78 crore (up 19.9% from Q3 FY24) and net profit of ₹73.99 crore (up 40.2% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 537.78 | 448.69 | +19.9% | 458.03 | +17.4% |
| Other income | 5.03 | 1.39 | +260.8% | 4.48 | +12.2% |
| Total income | 542.81 | 450.08 | +20.6% | 462.51 | +17.4% |
| Profit before tax | 100.63 | 73.82 | +36.3% | 71.77 | +40.2% |
| Net profit for the period | 73.99 | 52.76 | +40.2% | 54.62 | +35.5% |
| EPS, basic (₹) | 8.16 | 5.82 | +40.2% | 6.03 | +35.3% |
| Net margin (%) | 13.8 | 11.8 | 11.9 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 470.95 | 373.03 | +26.3% | 377.29 | +24.8% |
| Other income | 11.94 | 0.20 | 60x | 2.95 | +305.1% |
| Total income | 482.88 | 373.23 | +29.4% | 380.24 | +27.0% |
| Profit before tax | 96.18 | 67.44 | +42.6% | 63.43 | +51.6% |
| Net profit for the period | 73.52 | 48.19 | +52.6% | 47.84 | +53.7% |
| EPS, basic (₹) | 8.11 | 5.32 | +52.4% | 5.28 | +53.6% |
| Net margin (%) | 15.6 | 12.9 | 12.7 |
Consolidated
- Filed with BSE
- 06 Feb 2025, 14:48 IST
- Board meeting
- 05 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2025, 14:48 IST
- Board meeting
- 05 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Audited
- Source
- XBRL filing on BSE